Effect of the time until thrombolysis onset on outcome.

<p>(A) Time dependent ROSC, (B) time dependent successful hospital discharge.</p

Time-outcome relation.

<p>Time of thrombolysis onset, CPR time after thrombolysis and total CPR duration in patients with and without successful CPR (A), in patients with hospital discharge vs. those who died (B), and in patients with hospital discharge versus those with secondary lethality after initially successful CPR.</p

Adverse events associated with resuscitation and thrombolysis.

<p>14 of 104 patients could be discharged with good neurological outcome.</p

DE versus RHC correlations.

<p>DE mPAP (B) was better correlated with RHC than sPAP (A). Dotted lines mark virtual best correlation of 1 and solid lines mark the real correlation. r indicates the correlation coefficient, sPAP indicates systolic pulmonary artery pressure.</p

Study flowchart in accordance to the STARD criteria.

<p>In phase 0 diagnostic criteria were evaluated in 164 patients undergoing DE and RHC. In phase 1 the calculated cut-off value for mPAP was validated in a cohort of patients with the suspicion of PH.</p

Analysis of relative differences and ROC analysis of mPAP for diagnosis of PH.

<p>A, the relative positive and negative deviation between DE and RHC were larger for sPAP than mPAP. B, ROC analysis reveal an excellent diagnostic accuracy of mPAP for the diagnosis of PH with an area under the curve (AUC) of 0.95.</p

Characteristics of 164 patients and indications for RHC.

<p>BMI indicates body mass index (kg/m²), RHC indicates right heart catheterization.</p

Echocardiographic values in patients with different β₁AR variants.

<p>LA indicates left atrium, LVEDD indicates left ventricular enddiastolic diameter, IVSDD indicates diastolic interventricular septum diameter, LVEF indicates left ventricular ejection fraction.</p

Cardiovascular medication in patients with different β₁AR variants.

<p>ACE indicates angiotensin converting enzyme, ARB indicates angiotensin receptor blocker.</p

Relative allele distribution in patients with and without AF.

<p>A, P389 variants, B, P49 variants, C, combined genotype of P389 and P49 variants.</p